Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Indian Journal of Hematology and Blood Transfusion
Published in: Indian Journal of Hematology and Blood Transfusion 1/2019

01-01-2019 | Short Communication

Evaluation of STic Expert® HIT Kit and Its Comparison with ID-PaGIA™ Test in Suspected Heparin-Induced Thrombocytopenia

Authors: Narender Kumar, Varun Uppal, Jasmina Ahluwalia, Pankaj Malhotra, Neelam Varma, Ashish Jain

Published in: Indian Journal of Hematology and Blood Transfusion | Issue 1/2019

Login to get access

Abstract

Heparin-induced thrombocytopenia (HIT) is an adverse drug reaction caused by heparin. HIT occurs due to IgG antibodies directed against heparin-bound platelet factor 4 (PF4). The aim of this study was to evaluate the STic® Expert HIT for detection of anti-PF4/heparin antibodies in comparison with ID-PaGIA™ kit. The results were further confirmed by Heparin-induced platelet aggregation test (HIPA). A total of 17 patients with a suspected diagnosis of HIT were enrolled. The 4 T scoring of each case was performed. Testing for HIT was carried out by ID-PaGIA™, STic® Expert HIT, and HIPA. Testing by STic® Expert HIT test demonstrated positivity in three cases while testing by ID-PaGIA™ test kit revealed four positive cases. Two of these cases were confirmed as HIT by HIPA. The study suggests that STic® Expert HIT an equally effective test, in combination with the 4T scoring system for detecting/excluding the diagnosis of HIT. A large number of cases are needed for validation.
Literature
1.
Greinacher A, Warkentin TE (2006) Recognition, treatment, and prevention of heparin induced thrombocytopenia: review and update. Thromb Res 118:165–176CrossRefPubMed
2.
Amiral J, Marfaing-Koka A, Poncz M, Meyer D (1998) The biological basis of heparin-induced thrombocytopenia. Platelets 9:77–91CrossRefPubMed
3.
Rice L (2004) Heparin-induced thrombocytopenia: myths and misconceptions (that will cause trouble for you and your patient). Arch Intern Med 164:1961–1964CrossRefPubMed
4.
Cummins D (1995) Which patients undergoing cardiopulmonary bypass should be assessed for development of heparin-induced thrombocytopenia? Thromb Haemost 73:890–895CrossRefPubMed
5.
Crowther MA, Cook DJ, Albert M, Williamson D, Meade M, Granton J et al (2010) The 4Ts scoring system for heparin-induced thrombocytopenia in medical-surgical intensive care unit patients. J Crit Care 25:287–293CrossRefPubMed
6.
Lo GK, Juhl D, Warkentin TE, Sigouin CS, Eichler P, Greinacher A (2006) Evaluation of pretest clinical score (4 T’s) for the diagnosis of heparin-induced thrombocytopenia in two clinical settings. J Thromb Haemost 4:759–765CrossRefPubMed
7.
Warkentin TE, Heddle NM (2003) Laboratory diagnosis of immune heparin-induced thrombocytopenia. Curr Hematol Rep 2:148–157PubMed
8.
Meyer O, Salama A, Pittet N, Schwind P (1999) Rapid detection of heparin-induced platelet antibodies with particle gel immunoassay (ID-HPF4). Lancet 354:1525–1526CrossRefPubMed
9.
Sachs UJ, von Hesberg J, Santoso S, Bein G, Bakchoul T (2011) Evaluation of a new nanoparticle-based lateral-flow immunoassay for the exclusion of heparin-induced thrombocytopenia (HIT). Thromb Haemost 106:1197–1202CrossRefPubMed
10.
Laffan M, Manning R (2011) Laboratory control of anticoagulant, thrombolytic and antiplatelet therapy. In: Bain BJ, Bates I, Laffan MA, Lewis SM (eds) Dacie and Lewis practical haematology, 11th edn. Elsevier Churchill Livingstone, London, pp 476–477
11.
Kapadia FN, Ketkar AS, Deshpande AS, Puri VC, Khodaiji SJ (2013) Evaluation of various laboratory assays in detection of heparin-induced thrombocytopenia in an adult general ICU. Int J Lab Hematol 35:137–143CrossRefPubMed
12.
Kotwal J, Chaudhary S, Manoj MG, Hasnain S, Nair V, Luthra M (2014) Heparin induced thrombocytopenia: incidence and laboratory approach to diagnosis in Indians. Indian J Pathol Microbiol 57:31–38CrossRefPubMed
13.
Sachan D, Gupta N, Agarwal P, Chaudhary R (2011) The utility of pre-test clinical scoring for clinical diagnosis of heparin-induced thrombocytopenia in cardiac surgery patients of a tertiary care centre in north India. Transfus Med 21:231–235CrossRefPubMed
14.
Berroëta C, Crespin M, Bouabdallah K, Pargade S, Huchet FX, Bourel P et al (2016) DiagnoSTic® performance of a new rapid lateral flow immunoassay in patients suspected of heparin-induced thrombocytopenia and its clinical consequences. Semin Thromb Hemost 42:69–74CrossRefPubMed
15.
Leroux D, Hezard N, Lebreton A, Bauters A, Suchon P, de Maistre E et al (2014) Prospective evaluation of a rapid nanoparticle-based lateral flow immunoassay (STic® Expert(®) HIT) for the diagnosis of heparin-induced thrombocytopenia. Br J Haematol 166:774–782CrossRefPubMed
16.
Vianello F, Sambado L, Scarparo P, Lombardi A, Bernardi D, Plebani M et al (2015) Comparison of three different immunoassays in the diagnosis of heparin-induced thrombocytopenia. Clin Chem Lab Med 53:257–263CrossRefPubMed
Metadata
Title
Evaluation of STic Expert® HIT Kit and Its Comparison with ID-PaGIA™ Test in Suspected Heparin-Induced Thrombocytopenia
Authors
Narender Kumar
Varun Uppal
Jasmina Ahluwalia
Pankaj Malhotra
Neelam Varma
Ashish Jain
Publication date
01-01-2019
Publisher
Springer India
Published in
Indian Journal of Hematology and Blood Transfusion / Issue 1/2019
Print ISSN: 0971-4502
Electronic ISSN: 0974-0449
DOI
https://doi.org/10.1007/s12288-018-0996-z

Other articles of this Issue 1/2019

Indian Journal of Hematology and Blood Transfusion 1/2019 Go to the issue

Images

Compound Heterozygote of Hb D-Punjab and Hb D-Iran; An Interesting Finding

Review Article

Applications of Next Generation Sequencing in Haematological Disorders—Indian Status: Updates from ISHBT 2018

Original Article

The Effect of Demographic Factors and VKORC1 1639 G>A Genotypes on Estimated Warfarin Maintenance Dose in Iranian Patients Under Warfarin Therapy

Editorial

CML in India: Are We There Yet?

Original Article

Red Cell Indices and Hemoglobin Profile of Newborn Babies with Both the Sickle Gene and Alpha Thalassaemia in Central India

Original Article

RHD Genotyping by Molecular Analysis of Hybrid Rhesus box in RhD-Negative Blood Donors from Iran
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits